02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
23:26 , Jun 28, 2019 |  BC Extra  |  Preclinical News

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic...
05:39 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Preliminary ORR 24% for Oncosec's Tavo plus Keytruda in Phase II for melanoma

OncoSec Medical Inc. (NASDAQ:ONCS) reported preliminary data from 21 evaluable metastatic/recurrent melanoma patients in the Phase IIb KEYNOTE-695 trial showing that Tavo tavokinogene telseplasmid/IL-12 plus Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to...
20:46 , Jan 26, 2018 |  BC Week In Review  |  Company News

Avacta, OncoSec combine technologies

Avacta Group plc (LSE:AVCT) and OncoSec Medical Inc. (NASDAQ:ONCS) partnered to combine Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s gene delivery technology ImmunoPulse. Avacta said the companies will work together to...
19:16 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

OncoSec reports preliminary Phase I data for ImmunoPulse IL-12 in TNBC

OncoSec Medical Inc. (NASDAQ:ONCS) reported preliminary data from two evaluable heavily pretreated patients with metastatic triple-negative breast cancer (TNBC) in the Phase I OMS-I140 trial showing that a single cycle of intratumoral ImmunoPulse IL-12 (OMS...
00:02 , Dec 7, 2017 |  BC Extra  |  Company News

Management Tracks: Sunesis, Vital

Cancer company Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said President and CEO Daniel Swisher will step down, effective Dec. 31. He will join Jazz Pharmaceuticals plc (NASDAQ:JAZZ) as president and COO. Director Dayton Misfeldt will serve as...
23:28 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

OncoSec reports data from Phase II for ImmunoPulse IL-12 and Keytruda combo

OncoSec Medical Inc. (NASDAQ:ONCS) reported data from the Phase II OMS I-102 trial in 22 melanoma patients predicted to be PD-1 non-responders showing that ImmunoPulse IL-12 (OMS ElectroImmunotherapy, DNA IL-12) plus PD-1 mAb Keytruda pembrolizumab...
00:18 , Nov 9, 2017 |  BC Extra  |  Company News

Management tracks: Pfizer, Hansa

Pfizer Inc. (NYSE:PFE) hired Amrit Ray as global president of Pfizer essential health, R&D, effective Friday. He was SVP of external affairs at Johnson & Johnson (NYSE:JNJ). In his new role, Ray will be responsible...
18:48 , May 12, 2017 |  BC Week In Review  |  Company News

OncoSec to conduct Phase II melanoma trial combining its ImmunoPulse IL-12 and Keytruda

OncoSec Medical Inc. (NASDAQ:ONCS) said it will sponsor and conduct the Phase II PISCES trial to evaluate its ImmunoPulse IL-12 in combination with PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK). The trial...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

OMS ElectroImmunotherapy: Preliminary Phase II data

Preliminary data from 4 evaluable patients with treatment-refractory metastatic and unresectable SCCHN in the open-label, U.S. Phase II OMS-I130 trial showed that intratumoral ImmunoPulse IL-12 increased CD8+ T cell responses and led to 1 partial...